ATCOR develops and markets medical technologies that measure patient risk for hypertension, cardiovascular disease (CVD), and other related vascular disorders. We help clinicians with early detection of target organ damage and management of cardiovascular and renal disease.
Our SphygmoCor® technology enables researchers and clinicians to measure noninvasive central blood pressure (NcBP), the central arterial pressure waveform, central aortic pressures, and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the SphygmoCor® system, provides clinicians with better prognostic and diagnostic information to target interventions—effects which cannot be detected with standard brachial blood pressure measurement alone.
More than 4,000 SphygmoCor®systems are currently in use worldwide at major medical institutions, research institutions, and in various clinical trials with leading pharmaceutical companies. Our technology is featured in over 1,400 peer-reviewed publications in leading medical journals.
Under the ATCOR•X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable and connected fitness devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).ATCOR is a subsidiary of the Australian listed company CardieX Limited (ASX.CDX) www.cardiex.com